On September 16, 2021, ICER released its draft evidence report, “Tezepelumab for Severe Asthma: Effectiveness and Value.” This guide provides a framework for considering what aspects of the new treatment for asthma are important to patients and their families, and how to consider presenting those perspectives. This guide specifically provides insights about how to read and respond to ICER’s draft evidence report, as well as how to request a slot to make comments during ICER’s public meeting.
